HomeBusiness & Economics

Business & Economics

Seattle Genetics

Seattle Genetics Changes Corporate Name to Seagen

Seattle Genetics confirmed that it has changed it's corporate name to Seagen. According to a statement issued by the...

Cetuximab Saratolacan Approved in Japan for the Treatment of Unresectable Locally Advanced and Recurrent...

Japan’s Ministry of Health, Labour and Welfare has approved cetuximab saratolacan sodium (previously known as RM-1929; Akalux® IV Infusion...

Merck & Co and Seattle Genetics Sign Exclusive Licensing and Co-Development Agreement

Merck & Co and Seattle Genetics have signed an exclusive licensing and co-developing agreement to globally develop and commercialize...
Scientist pipetting

Gilead Acquires Immunomedics – Accelerating an Emerging and Complementary Oncology Pipeline

Just ahead of World ADC, the industry meeting for anyone involved in the development, manufacturing antibody-drug conjugates, and the...

Creating a New Single-digit Nanogram Containment Manufacturing Facility: MilliporeSigma Announces US $65 M Investment...

In a statement today, MilliporeSigma, the Life Science business of Merck KGaA, Darmstadt, Germany, confirmed a US $65 million...

Exelixis and Catalent to Jointly Develop Multiple SMARTag®-based Antibody-drug Conjugates

Alameda- (California-) based Exelixis confirmed that it has signed a partnership agreement with Catalent to develop multiple antibody-drug conjugates...

NBE-Therapeutics and Exelixis Sign Agreement to Advance Best-in-class ADCs Against Multiple Targets

Privately-owned Swiss biotech NBE-Therapeutics and Exelixis, confirmed a new partnership to discover and develop multiple antibody-drug conjugates (ADCs) for...

ADC Therapeutics On Track to File BLA for Loncastuximab Tesirine for R/R DLBCL later...

This week Swiss-based ADC Therapeutics, a late clinical-stage oncology-focused biotechnology company pioneering the development of antibody-drug conjugates (ADCs) for...

Daiichi Sankyo and AstraZeneca to Jointly Evaluate Patritumab Deruxtecan + Osimertinib in EGFR-Mutated...

Earlier this week Daiichi Sankyo and AstraZeneca confirmed that the companies had entered into a clinical trial collaboration with...

U.S. FDA Approves Belantamab Mafodotin as a Monotherapy in R/R Multiple Myeloma

The U.S. Food and Drug Administration has approved* belantamab mafodotin-blmf (Blenrep®; GlaxoSmithKline/GSK) as a monotherapy treatment for adult patients...